Twist Bioscience Corporation · NASDAQ:TWST
Twist Bioscience — Q1 FY2024 Earnings Presentation
17 slides from Twist Bioscience's earnings presentation, February 2024
Slide 1: Fiscal 2024 1Q Financial Results
Fiscal 2024 1Q Financial Results
Slide 2: Agenda
Agenda Welcome Angela Bitting SVP, Corporate Affairs; Chief ESG Officer Quarterly Highlights | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL Emily Leproust Chief Executive Officer Financial and Operational Performance Adam Laponis Chief Financial Officer Milestones Emily Leproust Chief Executive O
Slide 3: Legal Disclaimers
Legal Disclaimers This presentation contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private S
Slide 4: Highlights from the Quarter
Highlights from the Quarter $71.5 M $77.5 M 40.5% | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL Revenue Orders Gross Margin Beat guidance Strong orders Beat guidance of $67-68 M of 38-39% 4
Slide 5: Life Sciences Tools: Syn Bio Write
1 Life Sciences Tools SYN BIO WRITE 1Q 2024 Next Up ü Wilsonville, OR manufacturing launch | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL ü FoF-enabled new product introduction • $26.8 million in revenue § Synthetic genes: $19.7 million § Oligo pools: $4.2 million ü Express Genes § DNA libraries:
Slide 6: Life Sciences Tools: NGS Read
2 Life Sciences Tools NGS READ 1Q 2024 Next Up ü RNA sequencing workflow | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL ü Liquid biopsy growth (ongoing) • $39.4 million in revenue ü MRD growth (ongoing) • 44% of rev from top 10 customers • $43.3 million in orders Regulated products SNP microarray
Slide 7: Biopharma Solutions
3 BIOPHARMA SOLUTIONS 1Q 2024 Next Up ü Integrated offering | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL Scaling orders • $5.2 million in revenue Scaling revenue • $4.9 million in orders • Cautious optimism for sequential growth 7 For Research Use Only. Not for use in diagnostic procedures
Slide 8: Combined Biopharma Business Including Historical Abveris
3 BIOPHARMA SOLUTIONS Combined Biopharma Business Including Historical Abveris Broad Varied Disease Indications Modalities Cancer, Neurology, Immuno- mAbs, Bispecific Antibodies, VHH, oncology, Infectious Disease, ADC, Protein Engineering, More Poised to Deliver | TWIST BIOSCIENCE | PROPRIETARY and
Slide 9: Premium Solutions: DNA Data Storage
4 Premium Solutions DNA DATA STORAGE Reinventing Archive Storage • Refining enzymatic synthesis: lowest cost, aqueous-based, Century Archive shippable system Solution • Collaborating with Fortune 500 company on industrial-grade Valuable Optionality at CODEC Multiple Time Points • Demonstrated end-to
Slide 10: Strong Quarterly Revenue Growth
Strong Quarterly Revenue Growth $71.5 $66.9 $ in Millions $63.7 $60.2 $57.3 Biopharma $56.1 $54.2 NGS $48.1 SynBio $42.0 $38.0 | PROPRIETARY and CONFIDENTIAL $35.0 $32.4 $31.2 $28.2 $21.2 $19.3 $17.2 $15.7 $13.6 $13.6 $11.5 | TWIST BIOSCIENCE $8.4 $6.5 Jun Sep Dec Ma r Jun Sep Dec Ma r Jun Sep Dec M
Slide 11: Strong Quarterly Order Growth
Strong Quarterly Order Growth $77.5 $ in Millions $71.1 $64.7 $64.2 Biopharma $62.1 $63.8 $59.7 NGS $55.0 SynBio $49.6 $45.2 $42.7 $41.7 | PROPRIETARY and CONFIDENTIAL $39.1 $33.6 $24.8 $24.6 $24.7 $20.0 $18.1 $16.7 $15.2 $12.8 | TWIST BIOSCIENCE $10.7 $7.4 $8.5 $6.2 $4.5 Jun Sep Dec Ma r Jun Sep De
Slide 12: Revenue by Geography
Revenue by Geography $ in Millions Americas EMEA APAC | PROPRIETARY and CONFIDENTIAL | TWIST BIOSCIENCE Dec Ma r Jun Sep Dec Ma r Jun Sep Dec Ma r Jun Sep Dec Ma r Jun Sep Dec Ma r Jun Sep Dec Ma r Jun Sep Dec FY2018 FY2019 FY2020 FY2021 FY2022 FY2023 FY2024 12
Slide 13: Additional Financial Commentary
Additional Financial Commentary Revenue: $71.5M Orders: $77.5M Gross Margin: 40.5% R&D Expenses: $23.1M | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL SG&A Expenses: $52.8M Net Loss Attributable to Common Stockholders: $43M Cash, cash equivalents and short-term investments as of December 31, 2023
Slide 14: Managing Cash Burn
Managing Cash Burn Q2 FY2024 Guidance* FY2024 Guidance* $70-71M $288-293M ~$28.5M SynBio $114-117M SynBio Revenue ~$37-38M NGS $150-152M NGS ~$4.5M Biopharma ~$24M Biopharma GM 39% 40-41% | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL Operating Loss Before $189-194M Taxes CapEx ~$15M YE Cash Bala
Slide 15: Laying Groundwork for Revenue and Gross Margin Expansion in FY2024
Laying Groundwork for Revenue and Gross Margin Expansion in FY2024 1 SYN BIO WRITE 2 NGS READ 3 BIOPHARMA SOLUTIONS 4 DATA STORAGE • New opportunities in • Sequencer agnostic • Continue to enter into • Early access of Maker’s Market with discovery and Terabyte Century Express Genes • Large and growi
Slide 16: Scalable, Profitable Growth
Scalable, Profitable Growth Defined path to profitability New products, growth for margin expansion | TWIST BIOSCIENCE | PROPRIETARY and CONFIDENTIAL Consistent operational excellence Strong commercial execution in growing markets Continued revenue and market share growth Innovative Platform Large,
Slide 17: Writing the Future
e BIOSCIENCE Writing the Future